PROM1 and colorectal cancer: Some meta-analyses showed that CD133 was a biomarker of putative CSCs in many solid tumors and its positivity may be associated with poor overall survival in nonsmall-cell lung cancer [55], worse prognosis in patients with glioblastoma [20], and reduced overall survival in colorectal cancer [56].